医疗保险公司哈门那(HUM.US)盘前跌5.7%，报170.99美元。消息面上，哈门那去年第四季度营收为 326.4亿美元，超过分析师预期的320.8亿美元；调整后每股亏损3.96美元，去年同期每股亏损2.16美元， 分析师预期每股亏损4.01美元。展望2026年，公司给出保守的业绩指引，预计调整后每股收益至少为9 美元，低于分析师预期的11.87美元。(格隆汇) ...

格隆汇2月10日｜医疗保险公司CVS Health公布2025年第四季度业绩，营收同比增长超8%至1057亿美 元，高于分析师平均预期的1035.9亿美元；调整后每股收益同比下滑超8%至1.09美元，亦超过分析师预 期的0. 99美元。展望2026年，公司重申年收入至少达到4000亿美元的预期，维持调整后每股收益介乎7 至7.2美元的预期。 ...

Core Viewpoint - Mark Cuban criticizes the U.S. healthcare system, particularly high-deductible insurance plans, arguing that they financially burden everyday Americans while benefiting executives [1][2]. Group 1: Impact on Patients - Patients are facing increased costs due to high-deductible plans, leading to them paying full retail prices for medications for longer periods [2]. - Cuban estimates that patients may be collectively paying billions of dollars more due to these higher deductibles [2]. - Under the Affordable Care Act, rebates from drug purchases often benefit pharmacy benefit managers (PBMs) owned by the same insurance companies, exacerbating the financial strain on patients [2]. Group 2: Calls for Reform - Cuban advocates for significant structural reforms in the healthcare system, suggesting the breakup of large insurance companies and the divestment of non-insurance entities [3][4]. - He emphasizes the need for efficiency in the market, calling for similar actions against hospitals and pharmaceutical wholesalers [4]. Group 3: Consumer Access and Challenges - Critics argue that the healthcare system is too complex for patients to navigate effectively, but Cuban counters that consumers can and do shop for healthcare, citing his own experiences with Cost Plus Drugs [4]. - He highlights the challenges patients face in having their deductibles counted correctly, which complicates their ability to access affordable care [4].

Core Viewpoint - Wells Fargo downgraded the rating of health insurance company Hamanah from "Outperform" to "Hold," while maintaining the target price at $290 [1] Group 1 - The downgrade reflects a shift in the investment outlook for Hamanah, indicating potential concerns about its future performance [1] - The target price of $290 suggests that Wells Fargo sees limited upside potential from the current trading levels [1]

Core Viewpoint - President Trump's recent statements pose a negative outlook for insurance companies, as he plans to convene them to discuss price reductions due to their substantial profits [1][2][3]. Group 1: Impact on Insurance Companies - Trump announced he will meet with large insurance companies to advocate for price reductions, suggesting they could cut prices by 50% to 70% given their high profits [3]. - Following Trump's comments, stock prices of major health insurance companies, including UnitedHealth Group, Cigna, and Humana, experienced significant declines, with UnitedHealth Group dropping nearly 1% after initially rising [2][3]. - The American Health Insurance Plans association stated that premiums reflect medical costs and that insurance companies are working hard to protect Americans from rising healthcare costs [4]. Group 2: Drug Pricing Agreements - Trump announced agreements with nine pharmaceutical companies aimed at lowering drug prices for Americans in exchange for a three-year delay on tariffs [6]. - Fourteen out of the largest seventeen pharmaceutical companies have agreed to significantly reduce drug prices, which Trump claims is a major victory for patient affordability [6][7]. - The agreements are intended to provide certainty in drug pricing policies while avoiding high tariffs for pharmaceutical companies [7]. Group 3: Broader Economic Context - Rising healthcare costs and other consumer price increases have heightened public dissatisfaction with the economy, potentially influencing upcoming elections [4]. - Republican lawmakers are pushing for bipartisan healthcare reforms to protect voters in swing districts ahead of the midterm elections [4].

Group 1 - Jefferies raised the target price for health insurance company Hamanah from $253 to $313 [1] - The rating was upgraded from "Hold" to "Buy" [1]

Core Viewpoint - Centene Corporation reported a mixed performance in its latest earnings report, with adjusted earnings per share beating estimates but showing a decline compared to the previous year, while revenues increased significantly year over year [3][4]. Financial Performance - Centene's Q3 2025 adjusted earnings per share were 50 cents, surpassing the Zacks Consensus Estimate of a loss of 21 cents, but down from $1.62 per share in the prior year [3]. - Revenues increased by 18.2% year over year to $49.7 billion, exceeding the consensus mark by 4.4% [3]. - Premiums totaled $44.1 billion, up 22.2% year over year, driven by higher premiums and expanding membership in the Prescription Drug Plan (PDP) [6]. Revenue Breakdown - Medicaid revenues grew 9% year over year to $23.2 billion, while Medicare revenues surged 66% to $9.4 billion [5]. - Commercial revenues improved by 26% year over year to $11 billion [5]. - Service revenues decreased by 1.5% year over year to $772 million, although it beat estimates [7]. Membership and Costs - Total membership (excluding TRICARE) reached 28 million as of September 30, 2025, an 8% increase year over year [8]. - The health benefits ratio deteriorated to 92.7%, a decline of 350 basis points year over year [9]. - Operating expenses rose 37% year over year to $56.6 billion, driven by higher medical costs, which increased by 27% [9]. Cash Flow and Equity - Centene ended Q3 with cash and cash equivalents of $17.1 billion, up from $14.1 billion at the end of 2024 [11]. - Total stockholders' equity fell to $21 billion from $26.5 billion at the end of 2024 [12]. - The company generated $4.7 billion of net cash from operations in the first nine months of 2025, a significant increase from $741 million a year ago [12]. Share Repurchase - Centene repurchased common shares worth approximately $473 million in the first nine months of 2025 [13]. Market Sentiment and Outlook - There has been a downward trend in estimates, with the consensus estimate shifting down by 42.99% [14]. - Centene holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [16]. - The stock has a subpar Growth Score of D and a score of A on the value side, placing it in the top 20% for value investment strategy [15].

Centene Corporation Conference Call Summary Company Overview - **Company**: Centene Corporation (NYSE:CNC) - **Date of Conference**: November 11, 2025 - **Speakers**: Sarah London (CEO), Drew Asher (CFO) Key Points Industry Context - Centene operates primarily in the healthcare services sector, focusing on government-sponsored programs such as Medicaid and Medicare. Financial Performance - Q3 results exceeded expectations, leading to an upward revision of the full-year outlook to at least $2 per share [4][7] - The company reported a revenue stream of approximately $5 billion from the Florida Medicaid contract, which is expected to decrease to between $4.5 billion and $9.3 billion next year due to contract changes [8][9] Medicaid Updates - Centene was not awarded the CMS Florida contract after six years, impacting their revenue but allowing for a focus on sustainable margins [5][8] - The company is prioritizing a seamless transition for affected members and is not planning to protest the contract decision [5] - Medicaid margins are expected to remain consistent next year, contrasting with some peers who anticipate declines [15][36] Medicare and Marketplace Insights - Open enrollment for Medicare is ongoing, with a focus on margin improvement rather than membership growth [49][54] - The company is optimistic about its position in the Medicare Advantage market, aiming for break-even by 2027 [49] - There is an uptick in call volume related to Marketplace inquiries, indicating member confusion over premium changes [20][22] Legislative and Subsidy Discussions - Ongoing discussions in Congress regarding enhanced subsidies could significantly impact members and the overall market [24][25] - Centene has prepared for various scenarios regarding subsidy extensions and has built pricing for 2026 accordingly [26][30] Operational Strategies - The company is focused on improving margins through various levers, including rate negotiations and utilization management [15][17] - Centene is actively engaged with state governments to optimize Medicaid programs and address issues like fraud and waste [41][42] Future Outlook - The company sees potential for growth in Medicaid and is exploring disruptive opportunities in employer-sponsored insurance [59] - Centene aims to maintain a flexible capital structure, targeting a debt-to-capital ratio below 40% to seize future opportunities [58] Behavioral Health and Cost Management - Behavioral health accounts for approximately 20% of Medicaid spending, and states are increasingly focused on managing these costs [42][43] - Centene is working with states to implement effective policy changes to control costs while maintaining care quality [41] Conclusion - Centene is navigating a complex healthcare landscape with a focus on sustainable growth, margin improvement, and proactive engagement with legislative changes and state partnerships [59][60]

Core Insights - Humana reported Q3 earnings with a revenue increase of 11% year-over-year to $32.65 billion, surpassing analyst expectations of $32 billion [1] - Adjusted earnings per share were $3.24, exceeding the forecast of $2.82 [1] - The medical cost ratio was 91.1%, aligning with company guidance and slightly above the analyst expectation of 90.9% [1] - The company reaffirmed its full-year adjusted earnings per share guidance of approximately $17 [1]

Financial Data and Key Metrics Changes - The company reported revenues of $69.7 billion and adjusted earnings of $7.83 per share for Q3 2025, reflecting sustained growth despite a dynamic market environment [8][31]. - A net after-tax special item benefit of $61 million or $0.23 per share was recorded during the quarter [4]. Business Line Data and Key Metrics Changes - Evernorth Health Services generated revenues of $60.4 billion, with pre-tax adjusted earnings of $1.9 billion, in line with expectations [31]. - Specialty and care services revenues increased by 10% to $26.3 billion, with pre-tax adjusted earnings up 11% to $928 million, driven by strong specialty volume growth and increased biosimilar adoption [32]. - Pharmacy benefit services revenues were $34.1 billion, with pre-tax adjusted earnings of $1 billion, reflecting ongoing investments to improve patient experience [32]. Market Data and Key Metrics Changes - The company noted that generic drugs account for 90% of all prescriptions in the U.S., with prices being one-third cheaper than in other countries [10]. - Brand name medications continue to see significant price increases, with the median price for new FDA-approved drugs projected at approximately $390,000 for a treatment course in 2025 [11]. Company Strategy and Development Direction - The company is focusing on a new rebate-free model for pharmacy benefits, aimed at improving healthcare affordability and patient experience [9][15]. - Strategic investments, such as the acquisition of Shields Health Solutions, are intended to expand the company's capabilities in the specialty market [8][22]. - The company aims to transition at least 50% of its business to the new pharmacy benefits model by the end of 2028 [16]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth despite challenges, reaffirming an adjusted EPS outlook of at least $29.60 for 2025 [18][34]. - The company anticipates margin pressure in the pharmacy benefit services segment over the next two years due to strategic investments and contract renewals [17][28]. - Management highlighted the importance of public-private partnerships and innovation in addressing healthcare challenges [75][78]. Other Important Information - The company reported a debt to capitalization ratio of 44.9% as of September 30, 2025, primarily due to debt issuance related to the investment in Shields Health Solutions [35]. - The company expects strong cash flow from operations in the fourth quarter, consistent with previous patterns [35]. Q&A Session Summary Question: Clarification on pharmacy business and renewal pricing - Management confirmed that the new rebate-free model is designed to be transparent and fee-based, aligning with regulatory priorities, and that the long-term growth algorithm for Evernorth remains intact despite short-term challenges [41][42]. Question: Magnitude of expected decline in pharmacy benefit services - Management indicated that the expected decline in pharmacy benefit services income is due to large client renewals and transitional investment costs, with the decline being more than half attributable to the new margin profile from these renewals [56]. Question: Profitability of large contracts - Management clarified that while large contracts may have lower margins compared to the overall portfolio, they do not operate at a loss and are strategically important for the company [66][68]. Question: Adoption of the new pharmacy benefits model by employers - Management expressed confidence in the new model's appeal to employers, emphasizing its potential to simplify costs and improve employee satisfaction [62][63].